CLINICAL_TRIALS
trial_result
· 2024-05-02
Clinical Trial Update: Voxelotor Neurocognitive Function Study [Phase 3]
Summary
Phase 3 trial evaluating voxelotor for neurocognitive function in sickle cell disease was terminated; results were posted in May 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Sickle Cell Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-05-02